The EGFR/SFK pathway was found to mediate resistance to vemurafenib treatment in BRAF-mutant melanoma, and BRAF and EGFR/SFK inhibition was reported to block the proliferation and invasion of these tumors, providing potentially effective therapeutic options for these patients [66]. Here, BRAF is linked to melanoma.